Search results for "Percutaneous coronary intervention."

showing 10 items of 240 documents

Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care associ…

2022

Abstract Aims Cardiogenic shock (CS) is a life-threatening condition burdened by mortality in up to 50% of cases. Few recommendations exist with intermediate–low level of evidence on CS management and no data on adherence across centres exist. We performed a survey to frame CS management at multinational level. Methods and results An international cross-sectional survey was created and approved by European Society of Cardiology-Acute Cardiovascular Care Association board. A total of 337 responses from 60 countries were obtained. Data were assessed by the hospital level of care of the participants. The most common cause of CS was AMI (AMI-CS—79.9%) with significant difference according to ho…

DopamineShock CardiogenicGeneral MedicineCritical Care and Intensive Care MedicineNorepinephrineRecommendation adherenceCross-Sectional StudiesPercutaneous Coronary InterventionTreatment OutcomeDobutamineLactatesHumansCardiology and Cardiovascular MedicineSurveyCardiogenic shockMechanical and pharmacological managmentEuropean Heart Journal: Acute Cardiovascular Care
researchProduct

Decrease in annual incidence of acute coronary syndrome and restructuring of coronary care in Latvia

2014

Abstract Introduction Improvement in coronary heart disease prevention and treatment, as well as availability of coronary care facilities, is important for the reduction of acute coronary syndrome (ACS) incidence. Centralized acute coronary care system is crucial to provide optimal hospitalization and management algorithm for ACS patients. Aim The aim of the current report was to assess the annual incidence of ACS and the quality of acute coronary care in Latvia. Methods The Data from The Latvian Registry of Acute Coronary Syndromes were analyzed covering the time period from 2005 to 2010. Results Since the year 2005 the annual incidence of hospitalization due to ACS decreased significantly…

Emergency medical servicesmedicine.medical_specialtyAcute coronary syndromeInvasive strategybusiness.industryIncidence (epidemiology)medicine.medical_treatmentPrimary percutaneous coronary interventionPercutaneous coronary interventionmedicine.diseaseAnnual incidenceManagement algorithmEmergency medicinemedicineEmergency medical servicesRegistry dataAcute coronary syndromeIntensive care medicinebusinessCardiology and Cardiovascular MedicineCor et Vasa
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Relationships of growth factors, proinflammatory cytokines, and anti-inflammatory cytokines with long-term clinical results of autologous bone marrow…

2017

Aim The aim of the study was to test the hypothesis suggesting that the pre-intervention levels of proinflammatory cytokines, anti-inflammatory cytokines, and angiogenic growth factors predict the long-term clinical results of autologous bone marrow-derived mononuclear cell (ABMMC) transplantation in patients with primary ST elevation myocardial infarction (STEMI). Methods and results From 2003 to 2006, a total of 62 patients with primary STEMI were enrolled in an open randomized study registered under the title ESTABOMA. Patients were randomized into two groups: group 1 included patients treated with percutaneous coronary intervention (PCI) and ABMMC transplantation (n = 28); group 2 compr…

Male0301 basic medicinePhysiologyCardiovascular ProceduresCell Transplantationmedicine.medical_treatmentMyocardial InfarctionSocial Scienceslcsh:Medicine030204 cardiovascular system & hematologyPathology and Laboratory MedicineVascular MedicineGastroenterologyAnginaEndocrinology0302 clinical medicineImmune PhysiologyMedicine and Health SciencesBlood and Lymphatic System ProceduresPsychologyMyocardial infarctionlcsh:ScienceImmune ResponseBone Marrow TransplantationInnate Immune SystemMultidisciplinaryCardiac TransplantationAnginaMiddle AgedBrain natriuretic peptidesurgical procedures operativeCytokinesIntercellular Signaling Peptides and ProteinsFemaleInflammation MediatorsResearch Articlemedicine.medical_specialtySocial PsychologyImmunologyCardiologySurgical and Invasive Medical ProceduresTransplantation AutologousProinflammatory cytokine03 medical and health sciencesSigns and SymptomsDiagnostic MedicineGrowth FactorsInternal medicineчрескожное коронарное вмешательствоmedicineHumanscardiovascular diseasesInflammationTransplantationEndocrine Physiologybusiness.industrylcsh:RBiology and Life SciencesPercutaneous coronary interventionOrgan TransplantationMolecular Developmentmedicine.diseaseпровоспалительные цитокиныинфаркт миокардаTransplantation030104 developmental biologyImmune SystemHeart failureImmunologyConventional PCIтрансплантация мононуклеарных клетокlcsh:Qbusinessаутологичная трансплантация костного мозгаDevelopmental BiologyStem Cell Transplantation
researchProduct

Diabetes is Associated with Higher Trimethylamine N-oxide Plasma Levels

2016

Recent studies have revealed strong associations between systemic trimethylamine N-oxide (TMAO) levels, atherosclerosis and cardiovascular risk. In addition, plasma L-carnitine levels in patients with high TMAO concentrations predicted an increased risk for cardiovascular disease and incident major adverse cardiac events. The aim of the present study was to investigate the relation between TMAO and L-carnitine plasma levels and diabetes. Blood plasma samples were collected from 12 and 20 weeks old db/db mice and patients undergoing percutaneous coronary intervention. Diabetic compared to non-diabetic db/L mice presented 10-fold higher TMAO, but lower L-carnitine plasma concentrations at 12 …

Male0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentTrimethylamine N-oxideBody Mass IndexMethylaminesMice03 medical and health scienceschemistry.chemical_compoundEndocrinologyInsulin resistanceInterquartile rangeCarnitineDiabetes mellitusInternal medicineBlood plasmaDiabetes MellitusInternal MedicineAnimalsHumansMedicineCarnitineAgedbusiness.industryAge FactorsPercutaneous coronary interventionGeneral MedicineMiddle Agedmedicine.diseaseDisease Models Animal030104 developmental biologyEndocrinologychemistryCardiovascular DiseasesFemalebusinessBody mass indexmedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated hep…

2003

Item does not contain fulltext OBJECTIVES: The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial. BACKGROUND: In the ASSENT-3 trial, co-therapy with abciximab (ABC) or enoxaparin (ENOX) reduced ischemic complications after ST-elevation acute myocardial infarction treated with tenecteplase when compared with unfractionated heparin (UFH). The effect of these new co-therapies on the results of PCI is unknown. METHODS: Clinical outcomes in patients who received co-therapy with ABC, ENOX, or UFH and subsequently underwent an elective (n = 1,064) or urgent (n = 716) PCI in the ASSEN…

MaleAbciximabmedicine.medical_treatmentMyocardial InfarctionAlbertaBelgiumRecurrenceGermanyAbciximabAngioplasty Balloon CoronaryHeart lung and circulation [UMCN 2.1]Netherlandseducation.field_of_studyAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyElective Surgical ProceduresTissue Plasminogen ActivatorDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineEnoxaparin sodiummedicine.drugmedicine.medical_specialtymedicine.drug_classPopulationLow molecular weight heparinTenecteplasePlatelet Glycoprotein GPIIb-IIIa ComplexDrug Administration ScheduleImmunoglobulin Fab FragmentsFibrinolytic AgentsInternal medicineNorth CarolinamedicineHumansEnoxaparineducationEmergency TreatmentSwedenHeparinbusiness.industryAnticoagulantsPercutaneous coronary interventionSurvival AnalysisSurgerySpainConventional PCITenecteplasebusinessFibrinolytic agentJournal of the American College of Cardiology
researchProduct

On versus off-hour care of patients with acute coronary syndrome and persistent ST-segment elevation in certified German chest pain units

2016

BACKGROUND Regional healthcare projects improve the off-hour care of patients with acute coronary syndromes and persistent ST-segment elevation myocardial infarction (STEMI). To analyse differences in quality of care between on and off-hour care of STEMI patients admitted to certified German chest pain units. METHODS A total of 1107 STEMI patients from the German chest pain unit registry were enrolled. Analyses comprised critical time intervals (symptoms to first medical contact (FMC), FMC to admission, symptoms to admission, symptoms to balloon, FMC to balloon, door to balloon times) and major adverse cardiac and cerebrovascular events at follow-up. RESULTS 54.8% of patients were admitted …

MaleAcute coronary syndromePercutaneousmedicine.medical_treatmentMedizin030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineBioinformaticsBalloonChest painTime-to-Treatment03 medical and health sciences0302 clinical medicineAfter-Hours CareGermanyMyocardial RevascularizationmedicineHumansST segment030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeAngioplasty Balloon CoronaryAgedbusiness.industryPercutaneous coronary interventionGeneral MedicineMiddle Agedmedicine.diseaseAnesthesiaDoor-to-balloonST Elevation Myocardial InfarctionFemalemedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Invasive treatment of NSTEMI patients in German Chest Pain Units - Evidence for a treatment paradox.

2018

Background: Patients with non ST-segment elevation myocardial infarction (NSTEMI) represent the largest fraction of patients with acute coronary syndrome in German Chest Pain units. Recent evidence on early vs. selective percutaneous coronary intervention (PCI) is ambiguous with respect to effects on mortality, myocardial infarction (MI) and recurrent angina. With the present study we sought to investigate the prognostic impact of PCI and its timing in German Chest Pain Unit (CPU) NSTEMI patients. Methods and results: Data from 1549 patients whose leading diagnosis was NSTEMI were retrieved from the German CPU registry for the interval between 3/2010 and 3/2014. Follow-up was available at m…

MaleAcute coronary syndromemedicine.medical_specialtyChest Painmedicine.medical_treatmentMedizin030204 cardiovascular system & hematologyChest painRevascularizationLower riskAnginaCohort Studies03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineGermanyMedicineHumans030212 general & internal medicineMyocardial infarctioncardiovascular diseasesddc:610Hospital MortalityProspective StudiesRegistriesNon-ST Elevated Myocardial InfarctionAgedAged 80 and overEvidence-Based Medicinebusiness.industryPercutaneous coronary interventionMiddle Agedmedicine.diseaseTreatment OutcomeConventional PCICardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesInternational journal of cardiology
researchProduct

Percutaneous coronary intervention and recurrent hospitalizations in elderly patients with non ST-segment acute coronary syndrome: The role of frailty

2017

MaleAcute coronary syndromemedicine.medical_specialtyTime FactorsFrail Elderlymedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyPatient ReadmissionElectrocardiography03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicinemedicineHumansST segmentProspective Studies030212 general & internal medicineAcute Coronary SyndromeAgedbusiness.industryPercutaneous coronary interventionmedicine.diseaseTreatment OutcomeConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Plaque and blood vulnerability in ST segment elevation myocardial infarction patients: association between lesion morphology using intravascular ultr…

2013

AIM The purpose of the study was to evaluate associations between iMap intravascular ultrasound tissue characterization of culprit and nonculprit lesions in infarct-related artery and plasma biomarkers during ST segment elevation myocardial infarction (STEMI) and at 10-month follow-up. METHODS AND RESULTS Sixty-three STEMI patients at the time of index hospitalization and 10-month follow-up underwent coronary angiography and intravascular ultrasound with iMap tissue characterization of the culprit artery. Proximal and culprit segments were analyzed. A higher percentage of necrotic tissue in the nonculprit segment was found in patients in the top soluble intercellular adhesion molecule 1 (sI…

MaleAcute coronary syndromemedicine.medical_specialtyTime FactorsMyocardial InfarctionCoronary AngiographyCulpritLesionchemistry.chemical_compoundNecrosisPercutaneous Coronary InterventionPredictive Value of TestsInternal medicineIntravascular ultrasoundPlasminogen Activator Inhibitor 1medicineST segmentHumansMyocardial infarctionProspective StudiesUltrasonography InterventionalAgedmedicine.diagnostic_testbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseIntercellular Adhesion Molecule-1Coronary VesselsFibrosisPlaque Atheroscleroticmedicine.anatomical_structureTreatment OutcomechemistryPlasminogen activator inhibitor-1CardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersArteryCoronary artery disease
researchProduct